Compare IVT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVT | PGEN |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 2005 | 2013 |
| Metric | IVT | PGEN |
|---|---|---|
| Price | $31.53 | $4.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $34.38 | $13.67 |
| AVG Volume (30 Days) | 554.8K | ★ 7.3M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | ★ 647.37 | N/A |
| EPS | ★ 0.33 | 0.12 |
| Revenue | ★ $299,169,000.00 | $230,981,000.00 |
| Revenue This Year | $13.44 | $2,380.31 |
| Revenue Next Year | $5.81 | $84.01 |
| P/E Ratio | $95.42 | ★ $37.79 |
| Revenue Growth | ★ 9.20 | N/A |
| 52 Week Low | $27.44 | $3.04 |
| 52 Week High | $37.22 | $8.98 |
| Indicator | IVT | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.86 | 34.68 |
| Support Level | $30.49 | $3.65 |
| Resistance Level | $31.71 | $5.75 |
| Average True Range (ATR) | 0.67 | 0.47 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 63.64 | 19.48 |
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.